These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29078745)

  • 21. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
    Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
    Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates.
    Neumann-Fraune M; Beggel B; Pfister H; Kaiser R; Verheyen J
    J Med Virol; 2013 May; 85(5):775-9. PubMed ID: 23408582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High replicative full-length lamivudine-resistant hepatitis B virus isolated during acute exacerbations.
    Zhang JM; Yao X; Wang YX; Liu F; Ma ZM; Weng XH; Wen YM
    J Med Virol; 2005 Oct; 77(2):203-8. PubMed ID: 16121368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes.
    Selabe SG; Song E; Burnett RJ; Mphahlele MJ
    J Med Virol; 2009 Jun; 81(6):996-1001. PubMed ID: 19382250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of hepatitis B virus rtS117F substitution as a compensatory mutation for rtM204I during lamivudine therapy.
    Lin CL; Chien RN; Hu CC; Lai MW; Yeh CT
    J Antimicrob Chemother; 2012 Jan; 67(1):39-48. PubMed ID: 22001270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
    Chen CH; Lee CM; Tung WC; Wang JH; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
    J Hepatol; 2010 Apr; 52(4):478-85. PubMed ID: 20185198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-time PCR detection of multiple lamivudine-resistant mutations with displacing probes in a single tube.
    Wen H; Li Q
    J Clin Virol; 2007 Apr; 38(4):334-40. PubMed ID: 17329165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.
    Vincenti D; Piselli P; Solmone M; D'Offizi G; Capobianchi MR; Menzo S
    Antiviral Res; 2017 Jul; 143():62-68. PubMed ID: 28322924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
    Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
    J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation.
    Bartholomew MM; Jansen RW; Jeffers LJ; Reddy KR; Johnson LC; Bunzendahl H; Condreay LD; Tzakis AG; Schiff ER; Brown NA
    Lancet; 1997 Jan; 349(9044):20-2. PubMed ID: 8988118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
    Santos EA; Sucupira MV; Arabe J; Gomes SA
    BMC Infect Dis; 2004 Aug; 4():29. PubMed ID: 15339340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B virus genetic diversity.
    Echevarría JM; Avellón A
    J Med Virol; 2006; 78 Suppl 1():S36-42. PubMed ID: 16622876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel pattern (sW195a) in surface gene of HBV DNA due to YSDD (L180M plus M204S) mutation selected during lamivudine therapy and successful treatment with adefovir dipivoxil.
    Bozdayi AM; Eyigun CP; Turkyilmaz AR; Avci IY; Pahsa A; Yurdaydin C
    J Clin Virol; 2004 Sep; 31(1):76-7. PubMed ID: 15288618
    [No Abstract]   [Full Text] [Related]  

  • 35. Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine.
    Geipel A; Seiz PL; Niekamp H; Neumann-Fraune M; Zhang K; Kaiser R; Protzer U; Gerlich WH; Glebe D;
    Antivir Ther; 2015; 20(8):779-87. PubMed ID: 25560463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy.
    van Bömmel F; Trojan J; Deterding K; Wedemeyer H; Wasmuth HE; Hüppe D; Möller B; Bock FJ; Feucht HH; Berg T
    Antivir Ther; 2012; 17(6):1049-58. PubMed ID: 22892524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation.
    Ji D; Liu Y; Li L; Xu Z; Si LL; Dai JZ; Li X; Wang L; Yao Z; Xin SJ; Chen GF; Xu D
    J Clin Virol; 2012 May; 54(1):66-72. PubMed ID: 22398037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual-probe assay for detection of lamivudine-resistance hepatitis B virus by real-time PCR.
    Geng H; Hua B; Wang H; Cao Y; Sun Y; Yu A
    J Virol Methods; 2006 Mar; 132(1-2):25-31. PubMed ID: 16198006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
    Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R
    J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pyrosequencing for detection of lamivudine-resistant hepatitis B virus.
    Lindström A; Odeberg J; Albert J
    J Clin Microbiol; 2004 Oct; 42(10):4788-95. PubMed ID: 15472342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.